IL1B and metabolic dysfunction-associated steatotic liver disease: They exhibit anti-inflammatory properties by inhibiting pathways that lead to the activation of pro-inflammatory cytokines, such as IL-1β, IL-18, and TNF-α, which are linked to MASLD progression [199,200].